Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis demonstrates higher metabolic syndrome prevalence in postmenopausal women compared to premenopausal women, suggesting careful evaluation before hormone therapy.
The prevalence of MetS is relatively high in postmenopausal women and was more prevalent among postmenopausal than premenopausal women. Menopausal hormone therapy should be used with caution in patients with MetS, as its safety has not yet been evaluated among MetS patients and meticulous evaluation of each individual patient before starting MHT is needed.
No takes yet. Share an insight, caveat, or question.
Hallajzadeh et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: